Schering-Plough starts late-stage study |
|
|
|
Published
:
Mon, 22 Oct 2007 13:07
|
KENILWORTH, N.J. (AP) - Drug developer Schering-Plough Corp. said Monday it started dosing vascular disease patients with its stroke drug candidate in a late-stage study.The thrombin receptor antagonist is an antiplatelet drug aimed at keeping platelets from sticking together. Aspirin is a common antiplatelet medicine.The Phase III clinical program is expected to involve 30,000 patients with vascular disease. The first study will involve about 19,500 patients who have previously had a stroke.The company said patients undergoing angioplasty and treated with the drug in an already completed Phase II clinical trial had a lower number of strokes. The Phase II study was not designed to establish the drug's effectiveness.The company also said midstage study results showed the drug candidate did not increase a patients' risk of bleeding. Those results confirm safety results seen in previous studies, the company said.Shares of Schering-Plough rose 86 cents, or 2.6 percent, to $33.57 in premarket trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Schering-Plough takeover of Organon BioSciences gets EU go ahead 